Moucun Yuan

Dr. Moucun Yuan


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2019 in Antibodies
Verified
Journal Article
Open access
PDF file
MFMorse Faria
Morse Faria
MPMarlking Peay
Marlking Peay
BLBrandon Lam
Brandon Lam
EMEric Ma
Eric Ma
MYMoucun Yuan
Moucun Yuan
ARAnton Rosenbaum
Anton Rosenbaum
Bioanalysis of complex biotherapeutics, such as antibody-drug conjugates (ADCs), is challenging and requires multiple assays to describe their pharmacokinetic (PK) profiles. To enable exposure-safety and exposure-efficacy analyses, as well as to understand the metabolism of ADC therapeutics, three bioanalytical methods are typically employed: Total Antibody, Antibody Conjugated Toxin or Total ADC and Unconjugated Toxin. MEDI4276 is an ADC comprised of biparatopic humanized antibody attached via a protease-cleavable peptide-based maleimidocaproyl linker to a tubulysin toxin (AZ13599185) with an approximate average drug-antibody ratio of 4. The conjugated payload of MEDI4276 can undergo ester hydrolysis to produce the conjugated payload AZ13687308, leading to the formation of MEDI1498 (de-acetylated MEDI4276). In this report, we describe the development, validation and application of three novel multiplex bioanalytical methods. The first ligand-binding liquid chromatography coupled with tandem mass spectrometry (LBA-LC-MS/MS) method was developed and validated for simultaneous measurement of total antibody and total ADC (antibody-conjugated AZ13599185) from MEDI4276. The second LBA-LC-MS/MS assay quantified total ADC (antibody-conjugated AZ13687308) from MEDI1498. The third multiplex LC-MS/MS assay was used for simultaneous quantification of unconjugated AZ13599185 and AZ13687308. Additional stability experiments confirmed that quantification of the released warhead in the presence of high concentrations of MEDI4276 was acceptable. Subsequently, the assays were employed in support of a first-in-human clinical trial (NCT02576548).


28 November 2018 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
SSStephen P. Schauer
Stephen P. Schauer
WMWilliam R. MylottJr
William R. MylottJr
MYMoucun Yuan
Moucun Yuan
RJRand G. Jenkins
Rand G. Jenkins
WMW. Rodney Mathews
W. Rodney Mathews
KWKristin R. Wildsmith
Kristin R. Wildsmith
Amyloid-β 1–42 (Aβ1–42) peptide is a well-established cerebrospinal fluid (CSF) biomarker for Alzheimer’s disease (AD). Reduced levels of Aβ1–42 are indicative of AD, but significant variation in the absolute concentrations of this analyte has been described for both healthy and diseased populations. Preanalytical factors such as storage tube type are reported to impact Aβ recovery and quantification accuracy. Using complementary immunological and mass spectrometry-based approaches, we identified and characterized preanalytical factors that influence measured concentrations of CSF Aβ peptides in stored samples. CSF from healthy control subjects and patients with AD was aliquoted into polypropylene tubes at volumes of 0.1 ml and 0.5 ml. CSF Aβ1–42 concentrations were initially measured by immunoassay; subsequent determinations of CSF Aβ1–42, Aβ1–40, Aβ1–38, Aβ1–37, and Aβ1–34 concentrations were made with an absolute quantitative mass spectrometry assay. In a second study, CSF from healthy control subjects and patients with dementia was denatured with guanidine hydrochloride (GuHCl) at different stages of the CSF collection and aliquoting process and then measured with the mass spectrometry assay. Two distinct immunoassays demonstrated that CSF Aβ1–42 concentrations measured from 0.5-ml aliquots were higher than those from 0.1-ml aliquots. Tween-20 surfactant supplementation increased Aβ1–42 recovery but did not effectively resolve measured concentration differences associated with aliquot size. A CSF Aβ peptide mass spectrometry assay confirmed that Aβ peptide recovery was linked to sample volume. Unlike the immunoassay experiments, measured differences were consistently eliminated when aliquots were denatured in the original sample tube. Recovery from a panel of low-retention polypropylene tubes was assessed, and 1.5-ml Eppendorf LoBind® tubes were determined to be the least absorptive for Aβ1–42. A comparison of CSF collection and processing methods suggested that Aβ peptide recovery was improved by denaturing CSF earlier in the collection/aliquoting process and that the Aβ1–42/Aβ1–40 ratio was a useful method to reduce variability. Analyte loss due to nonspecific sample tube adsorption is a significant preanalytical factor that can compromise the accuracy of CSF Aβ1–42 measurements. Sample denaturation during aliquoting increases recovery of Aβ peptides and improves measurement accuracy. The Aβ1–42/Aβ1–40 ratio can overcome some of the quantitative variability precipitated by preanalytical factors affecting recovery.

17 December 2025 in Bioanalysis
Verified
Journal Article
Closed access
YHYu Gus Hui
Yu Gus Hui
FWFang Wang
Fang Wang
JWJian Wu
Jian Wu
EDEmmalyn Dupree
Emmalyn Dupree
MWM. Shane Woolf
M. Shane Woolf
WMWilliam R. Mylott
William R. Mylott
Hybrid LC - MS/MS methodology offers orthogonal ADA quantitation but is limited by endogenous immunoglobulin matrix interference challenges. We developed a novel semi-quantitative LC-MS/MS isotyping assay for rabbit IgG/IgM immunogenicity in K2EDTA plasma using double immunoprecipitation with double acid dissociation. As compared to single immunoprecipitation, double immunoprecipitation reduced endogenous IgG by ≥90% and IgM by >95% (W1B1) or >55% (W3B2), improved peak-area ratios, and achieved an LLOQ of 100 ng/mL, with acceptable accuracy and precision. Double immunoprecipitation plus acid dissociation mitigates matrix interference and enables robust semi-quantitative hybrid LC-MS/MS ADA isotyping in rabbit plasma.

7 October 2026 in Bioanalysis
Verified
Journal Article
Closed access
YHYu Gus Hui
Yu Gus Hui
JWJian Wu
Jian Wu
KSKumar Shah
Kumar Shah
RMRoberto C. Mendez
Roberto C. Mendez
XSXueqian Su
Xueqian Su
WMWilliam Mylott
William Mylott
1. Globally, neurological disorders are a leading cause of disability [1]. Among these disorders, Parkinson’s disease (PD) has the fastest-growing prevalence rate [2,3]. PD is a progressive neurode...